Screening of anticancer drugs for chemoembolization of hepatocellular carcinoma

Anti-Cancer Drugs

Volumn 22, Issue 8, 2011, Pages 741-748

  Boulin, Mathieu ^a,d   Guiu, Séverine ^d,e   Chauffert, Bruno ^d,e   Aho, Serge ^b   Cercueil, Jean Pierre ^b,d   Ghiringhelli, François ^d,e   Krause, Denis ^b   Fagnoni, Philippe ^a,d   Hillon, Patrick ^c,d   Bedenne, Laurent ^c,d   Guiu, Boris ^a,b,d  

^a DIJON UNIVERSITY HOSPITAL   (France)

^b Department of Epidemiology ^*  (France)

^c University Hospital   (France)

^d UNIVERSITÉ DE BOURGOGNE   (France)

^e Georges Francois Leclerc Center   (France)

Author keywords

anticancer drugs; chemoembolization; hepatocellular carcinoma

Indexed keywords

CARBOPLATIN; CISPLATIN; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; GEMCITABINE; IDARUBICIN; MITOMYCIN C; MITOXANTRONE; OXALIPLATIN; PACLITAXEL;

ARTICLE; CANCER CELL CULTURE; CELL DEATH; CELL STRAIN HEPG2; CHEMOEMBOLIZATION; COLORIMETRY; CONTROLLED STUDY; CYTOTOXICITY; DRUG SCREENING; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER CELL CARCINOMA; MALE; NONLINEAR REGRESSION ANALYSIS; PRIORITY JOURNAL; QUANTITATIVE ASSAY;

ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CHEMOEMBOLIZATION, THERAPEUTIC; COLORIMETRY; DOSE-RESPONSE RELATIONSHIP, DRUG; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS; NONLINEAR DYNAMICS; REGRESSION ANALYSIS;

EID: 80051548044     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0b013e328346a0c5     Document Type: Article

References (40)

1. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007; 32: 2257-2276.
2. Altekruse SF, McGlynn KA, Reichmann ME. Hepatocellular carcinoma incidence, mortality and survival trends in the United States from 1975 to 2005. J Clin Oncol 2009; 27:485-491.
3. Bruix J, Llovet JM. Major achievements in hepatocellular carcinoma. Lancet 2009; 373:614-616.
4. Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008; 100:698-711.
5. Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT, et al. Randomized controlled trial of transarterial ethiodized oil chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002; 35:1164-1171. (Pubitemid 34454013)
6. Llovet JM, Real MI, Montana X, Planas R, Coll S, Aponte J, et al. Arterial embolization or chemoembolization versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002; 359:1734-1739. (Pubitemid 34607087)
7. Camma C, Schepis F, Orlando A, Albanese M, Shahied L, Trevisani F, et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized control trials. Radiology 2002; 224:47-54. (Pubitemid 34680374)
8. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003; 37:429-442. (Pubitemid 36152543)
9. Buijs M, Vossen JA, Frangakis C, Hong K, Georgiades CS, Chen Y, et al. Nonresectable hepatocellular carcinoma: long-term toxicity in patients treated with transarterial chemoembolization-single-center experience. Radiology 2008; 249:346-354.
10. Marelli L, Stigliano R, Triantos C, Senzolo M, Cholongitas E, Davies N, et al. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol 2007; 30:6-25. (Pubitemid 44900485)
11. Burroughs A, Hochhauser D, Meyer T. Systemic treatment and liver transplantation for hepatocellular carcinoma: two ends of the therapeutic spectrum. Lancet Oncol 2004; 5:409-418. (Pubitemid 38878044)
12. Petraccia L, Onori P, Sferra R, Lucchetta MC, Liberati G, Grassi M, et al. MDR (multidrug resistance) in clinical therapeutic implications. Clin Ter 2003; 154:325-335. (Pubitemid 44897497)
13. Park JG, Lee SK, Hong IG, Kim HS, Lim KH, Choe KJ, et al. MDR1 gene expression: its effect on drug resistance to doxorubicin in human hepatocellular carcinoma cell lines. J Natl Cancer Inst 1994; 86:700-705.
14. Minemura M, Tanimura H, Tabor E. Overexpression of multidrug resistance genes MDR1 and Cmoat in human hepatocellular carcinoma and hepatoblastoma cell lines. Int J Oncol 1999; 15:559-563.
15. Varela M, Real MI, Burrel M, Forner A, Sala M, Brunet M, et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol 2007; 46:474-481. (Pubitemid 46201723)
16. Malagari K, Chatzimichail K, Alexopoulou E, Kelekis A, Hall B, Dourakis S, et al. Transarterial chemoembolisation of unresectable hepatocellular carcinoma with drug eluting beads: results of an open-label study of 62 patients. Cardiovasc Interv Radiol 2008; 31:269-280.
17. Malagari K, Alexopoulou E, Chatzimichail K, Hall B, Koskinas J, Ryan S, et al. Transcatheter chemoembolization in the treatment of HCC in patients not eligible for curative treatments: midterm results of doxorubicin-loaded DC bead. Abdom Imaging 2008; 33:512-519.
18. Lammer J, Malagari K, Vogl T, Pilleul F, Denys A, Watkinson A, et al. Prospective randomized study of doxorubicin-eluting bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Interv Radiol 2010; 33:41-52.
19. Park JG, Lee JH, Kang MS, Park KJ, Jeon YM, Lee HJ, et al. Characterization of cell lines established from human hepatocellular carcinoma. Int J Cancer 1995; 62:276-282.
20. Royer B, Guardiola E, Polycarpe E, Hoizey G, Delroeux D, Combe M, et al. Serum and intraperitoneal pharmacokinetics of cisplatin within intraoperative intraperitoneal chemotherapy: influence of protein binding. Anticancer Drugs 2005; 16:1009-1016. (Pubitemid 41416092)
21. Seber GAF, Wild CJ. Nonlinear regression. New York: John Wiley & Sons Inc.; 1989.
22. Watanabe S, Nishioka M, Ohta Y, Ogawa N, Ito S, Yamamoto Y. Prospective and randomized controlled study of chemoembolization therapy in patients with advanced hepatocellular carcinoma: cooperative study group for liver cancer treatment in Shikoku area. Cancer Chemother Pharmacol 1994; (Suppl):S93-S96. (Pubitemid 24147974)
23. Kawai S, Tani M, Okamura J, Ogawa M, Oshashi Y, Monden M, et al. Prospective and randomized trial of lipiodol-transcatheter arterial chemoembolization for treatment of hepatocellular carcinoma: a comparison of epirubicin and doxorubicin (second cooperative study). The cooperative study group for liver cancer treatment of Japan. Semin Oncol 1997; 24 (Suppl):S6-S45.
24. Mok TS, Choi E, Yau D, Johri A, Yeo W, Chan AT, et al. Effects of patupilone (epotheline B; EPO906), a novel chemotherapeutic agent, in hepatocellular carcinoma: an in vitro study. Oncology 2006; 71:292-296. (Pubitemid 47289591)
25. Chuu JJ, Liu JM, Tsou MH, Huang CL, Chen CP,Wang HS, et al. Effects of paclitaxel and doxorubicin in histocultures of hepatocellular carcinomas. J Biomed Sci 2007; 14:233-244. (Pubitemid 46625402)
26. Chunhu Z, Suiyu H, Meiqun C, Guilin X, Yunhui L. Antiproliferative and apoptotic effects of paeonol on human hepatocellular carcinoma cells. Anticancer Drugs 2008; 19:401-409.
27. Broggini M, Italia C, Colombo T, Marmonti L, Donellim MG. Activity and distribution of i.v. and oral 4-demethoxydaunorubicin in murine experimental tumors. Cancer Treat Rep 1984; 68:739-747. (Pubitemid 14115200)
28. Roovers DJ, Van Vliet M, Bloem AC, Lokhorst HM. Idarubicin overcomes P-glycoprotein-related multidrug resistance: comparison with doxorubicin and daunorubicin in human multiple myeloma cell lines. Leuk Res 1999; 23:539-548. (Pubitemid 29258053)
29. Louafi S, Boige V, Ducreux M, Bonyhay L, Mansourbakht T, de Baere T, et al. Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC): results of a phase II study. Cancer 2007; 109:1384-1390. (Pubitemid 46466566)
30. Matsumoto K, Nagahara T, Okano J, Murawaki Y. The growth inhibition of hepatocellular and cholangiocellular carcinoma cells by gemcitabine and the roles of extracellular signal-regulated and checkpoint kinases. Oncol Rep 2008; 20:863-872.
31. Berman E, Heller G, Santorsa JA, McKenzie S, Gee T, Kempin S, et al. Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. Blood 1991; 77: 1666-1674.
32. Weiss MA, Drullinsky P, Maslak P, Scheinberg D, Golde DW. A phase I trial of a single high dose of idarubicin combined with high-dose cytarabine as induction therapy in relapsed or refractory adult patients with acute lymphoblastic leukemia. Leukemia 1998; 12:865-868. (Pubitemid 28287207)
33. Tumolo S, Toffoli G, Baerz A. Oral idarubicin for the treatment of hepatocellular carcinoma. Proc Am Soci Clin Oncol 2002; 21 (Suppl):S635.
34. Chauffert B, Martin M, Hammann A, Michel MF, Martin F. Amiodaroneinduced enhancement of doxorubicin and 40-deoxydoxorubicin cytotoxicity to rat colon cancer cells in vitro and in vivo. Cancer Res 1986; 46:825-830. (Pubitemid 16145444)
35. Pé rez-Tomàs R. Multidrug resistance: retrospect and prospects in anticancer drug treatment. Curr Med Chem 2006; 13:1859-1876.
36. Guiu B, Collin C, Cercueil JP, Loffroy R, Guiu S, Ferrant E, et al. Pilot study of transarterial chemoembolization with pirarubicin and amiodarone for unresectable hepatocellular carcinoma. Am J Clin Oncol 2009; 32:238-244.
37. Mankhetkorn S, Dubru F, Hesschenbrouck J, Fiallo M, Garnier-Suillerot A. Relation among the resistance factor, kinetics of uptake, and kinetics of the Pglycoprotein efflux of doxorubicin, daunorubicin, 8-(S)-fluoroidarubicin, and idarubicin in multidrug-resistant K562 cells. Mol Pharm 1996; 49:532-539.
38. Goebel M. Oral idarubicin: an anthracycline derivative with unique properties. Ann Hematol 1993; 66:33-43. (Pubitemid 23066935)
39. Berman E, McBride M. Comparative cellular pharmacology of daunorubicin and idarubicin in human multidrug-resistant leukemia cells. Blood 1992; 79:3267-3273.
40. Vander Borght S, Komuta M, Libbrecht L, Katoonizadeh A, Aerts R, Dymarkowski S, et al. Expression of multidrug resistance-associated protein 1 in hepatocellular carcinoma is associated with a more aggressive tumour phenotype and may reflect a progenitor cell origin. Liver Int 2008; 28:1370-1380.